Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors
NCT04673942 · View on ClinicalTrials.gov ↗
Study Summary
AdAPT-001 is an oncolytic virus that is injected directly into the tumor or via intraarterial administration. The purpose of this study is to find out if AdAPT-001 is safe and tolerable. The next step is to find out if AdAPT-001 if efficacious with or without a checkpoint inhibitor.
Conditions Studied
Interventions
- DRUG Checkpoint Inhibitor, Immune
- BIOLOGICAL AdAPT-001
Study Locations (6)
California
- City of Hope — Duarte
- California Cancer Associates for Research and Excellence, cCARE — San Marcos
- Providence Saint John's Health Center — Santa Monica
Texas
- Mary Crowley Cancer Research — Dallas
- MD Anderson Cancer Center — Houston
Ohio
- Cleveland Clinic — Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2021-03-29 |
| Est. Completion | 2027-03-01 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04673942
The ClinicalTrials.gov registry entry for NCT04673942 describes a study currently listed as recruiting. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EpicentRx, which has 5 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 6 conditions, with Cancer appearing as the primary indexed condition, and to 2 interventions — of which Checkpoint Inhibitor, Immune is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT04673942 reports 6 study locations spanning 3 distinct geographic areas — top geographies include California, Texas, Ohio. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT04673942 about?
NCT04673942 is a clinical study titled "A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors". AdAPT-001 is an oncolytic virus that is injected directly into the tumor or via intraarterial administration. The purpose of this study is to find out if AdAPT-001 is safe and tolerable. The next step is to find out if AdAPT-001 if efficacious with or without a checkpoint inhibitor.
What is the current status of trial NCT04673942?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 140 participants. The study started on 2021-03-29. Estimated completion is 2027-03-01.
What conditions does trial NCT04673942 study?
This clinical trial studies the following conditions: Cancer, Neoplasms, Sarcoma, Solid Tumor, Adult, Chondrosarcoma. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT04673942?
The interventions under investigation include: Checkpoint Inhibitor, Immune (DRUG), AdAPT-001 (BIOLOGICAL). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT04673942?
This trial is sponsored by EpicentRx, which has 5 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT04673942 being conducted?
This trial has 6 study locations across California, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.